Artificial Intelligence and the Future of the Drug Safety Professional.


Journal

Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 22 10 2018
medline: 3 1 2020
entrez: 22 10 2018
Statut: ppublish

Résumé

The healthcare industry, and specifically the pharmacovigilance industry, recognizes the need to support the increasing amount of data received from individual case safety reports (ICSRs). To cope with this increase, more healthcare and qualified professionals are required to capture and evaluate the data. To address the evolving landscape, it will be necessary to embrace assistive technologies such as artificial intelligence (AI) at scale. AI in the field of pharmacovigilance will possibly result in the transformation of the drug safety (DS) professional's daily work life and their career development. Celgene's Global Drug Safety and Risk Management (GDSRM) function has established a series of work activities to drive innovation across the pharmacovigilance value chain (Celgene Chrysalis Fact Sheet. https://www.celgene.com/newsroom/media-library/chrysalis-fact-sheet/, 2018). The development of AI in pharmacovigilance raises questions about the possible changes in DS professionals' lives, who may find themselves curious about their future roles in a workplace assisted by AI. We discuss the current state of pharmacovigilance and the DS professional, AI in pharmacovigilance and the potential skillsets a DS professional may require when working with AI. We also describe the results of research conducted at Celgene GDSRM. The objective of the research was to understand the thoughts of pharmacovigilance professionals about their jobs. These results are provided in the form of aggregated responses to interview questions based on a 12-part questionnaire [see the Electronic Supplementary Material (ESM)]. A sample of six DS professionals representing various areas of pharmacovigilance operations were asked a range of questions about their backgrounds, current roles and future expectations. The DS professionals interviewed were, overall, enthusiastic about their job roles potentially changing with AI enhancements. Interviewees suggested that AI would allow for pharmacovigilance resources, time, and skills to shift the work from a volume-based to a value-based focus. The results suggest that pharmacovigilance professionals wish to use their qualifications, skillsets and experience in work that provides more value for their efforts. Machine learning algorithms have the potential to enhance DS professionals' decision-making processes and support more efficient and accurate case processing.

Identifiants

pubmed: 30343417
doi: 10.1007/s40264-018-0746-z
pii: 10.1007/s40264-018-0746-z
pmc: PMC6450851
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-497

Auteurs

Karolina Danysz (K)

Celgene International Sàrl, Route de Perreux 1, 2017, Boudry, Switzerland. kdanysz@celgene.com.

Salvatore Cicirello (S)

Celgene International Sàrl, Route de Perreux 1, 2017, Boudry, Switzerland.

Edward Mingle (E)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Bruno Assuncao (B)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Niki Tetarenko (N)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Ruta Mockute (R)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Danielle Abatemarco (D)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Mark Widdowson (M)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Sameen Desai (S)

Celgene Corporation, 86 Morris Ave, Summit, NJ, 07901, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH